Abstract shows the value of UBC Rapid | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Bladder cancer

July 2019

Abstract shows the value of UBC Rapid

An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer.

IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US.

IDL Biotech has started the work on mapping the US market.

IDL Biotech launches TUBEX TF in Kenya

On September 17, 2019, IDL Biotech will launch the company's rapid test for typhoid fever, TUBEX TF, in Kenya.

IDL Biotech

Skip this intro